What Peppermint Venture Partners does

Peppermint Venture Partners (PVP) is a Berlin-based private venture capital firm investing in early-stage life science companies across Europe, with a primary focus on the DACH region, the UK and Scandinavia. The firm operates three distinct fund vintages: the original Peppermint VC 1 Fund (€21M, launched 2000, ICT/industrial technologies and life sciences), the Peppermint Charité Biomedical Fund (CBF 1, €30M, launched 2011, medtech, digital health and pharma platforms), and the forthcoming LIIDO Fund (€100M target, 2025) dedicated to technology-driven companies in the Life Science Tools & Services space. PVP's underlying model combines equity capital with active portfolio support: the firm leverages >100 years of combined partner experience, board representation in portfolio companies, and exclusive institutional relationships with Charité (since 2010) and the Helmholtz Association (since 2011, including external management of the Helmholtz Validation Fund) to source deals and accelerate commercialization.

PVP's core technology is its deal origination and value-add infrastructure rather than any product or platform. The firm sources through direct network engagement, research partnerships with Charité and the Helmholtz Association, and participation in programs such as EIT Health, EIC Accelerator and TechTour. Portfolio support includes board-level governance (chairs held at CEVEC, CellAct, Labforward, Emperra, Caterna; vice-chair at Implandata), operational mentorship from a venture partner with MedTech CEO experience, and active M&A orchestration, exemplified by the September 2024 labforward-LabTwin merger that brought Sartorius and TECAN onto the cap table. The firm is a subsidiary of Peppermint Holding GmbH, an industrial group founded by Managing Partner Ingeborg Neumann in 1997.

PVP generates revenue through traditional VC economics: periodic management fees on committed capital (typically ~2% annually across funds), episodic carried interest from exits, and a small adjacent revenue stream from its sister company PVP Advisors, which provides strategic advisory to research organizations and corporates. Demonstrated exits include Scienion AG (>13x return, now part of BICO), CEVEC Pharmaceuticals (acquired by Cytiva in October 2022), and CellAct Pharma (drug candidate CAP7.1 sold to MundiPharma), alongside IPOs of Epigenomics, Jerini and Santhera credited to Managing Partner Dr. Klaus Stöckemann's prior tenure at 3i plc. The firm's customer base in the LP sense is anchored by the Neumann family's Peppermint Holding, while its "downstream customers" are 16+ portfolio companies across two active funds.

Name

Peppermint Venture Partners

Legal name

Peppermint VenturePartners GmbH

Website

https://pvp.health

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

1–10 employees

Short description

Peppermint Venture Partners is a Berlin-based private venture capital firm managing three funds (€151M combined target) that invest in early-stage life science, medtech, and digital health companies across Europe, with institutional research partnerships at Charité and the Helmholtz Association.

Ownership category

akta.pro rank

Product category

Life Science Venture Capital

NAICS

Portfolio Management and Investment Advice (523940)

SIC

Investment Advice (6282)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

• Venture capital funding
• Life science investments
• Early-stage healthcare
• Medical technology investing
• Biotech venture capital

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Venture Capital Investment Returns: PVP generates returns through equity investments in early-stage life science companies. Returns come from trade sales, IPOs, and M&A exits. Notable exits include Scienion AG (>13x return), CEVEC Pharmaceuticals (sold to Cytiva), and multiple other portfolio companies.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Peppermint Venture Partners is a Berlin-based private venture capital firm that invests equity capital from its three sector-focused funds (VC 1, CBF 1, and LIIDO) into early-stage life science and healthcare companies in Europe, primarily DACH, the UK and Scandinavia. Beyond capital, it provides portfolio companies with strategic mentorship, network access through partnerships with Charité and the Helmholtz Association, and hands-on management support. Returns are realized through trade sales, IPOs and M&A exits, while sister entity PVP Advisors offers strategic advisory services to research organizations and foundations.

Product overview

Peppermint Venture Partners operates as a private venture capital firm managing three distinct investment funds: LIIDO (targeting €100 million for Life Science Tools & Services), Peppermint CBF 1 (€30 million for MedTech/Digital Health/Pharma Platforms), and the original VC 1 Fund (€21 million for ICT/Industrial/Life Sciences). The firm provides capital investment and hands-on management support to transformative life science companies, with a focus on disruptive innovations in Europe.

Differentiator

Problem solved

Functional benefit

Brands

• LIIDO: Laboratory Intelligence Innovations Digitalization and Operations - Fund investing in Life Science Tools & Services Space
• CBF 1
• VC 1

Products and services

• Peppermint VC 1 Fund Original Peppermint venture capital fund of €21M targeting ICT, industrial technologies and life sciences investments in Germany; achieved total return of >1.7x including a >13x exit on Scienion AG.
• Peppermint CBF 1 (Charité Biomedical Fund) Venture capital fund of €30M launched in 2010/2011 to invest in MedTech, Digital Health and Pharma Platforms across DACH; portfolio companies attracted €185M from co-investors (9.4x leverage).
• LIIDO Fund New Peppermint fund with a €100M target (Laboratory Intelligence Innovations Digitalization and Operations) investing in technology-driven Life Science Tools & Services companies with market traction and initial revenues in DACH, the UK and Scandinavia.
• PVP Advisors Spin-off/sister company of Peppermint VenturePartners providing strategic advice and support for research organizations, foundations and companies in the start-up and innovation ecosystem.

Quantifiable outcome

• VC 1 achieved >1.7x total return
• +2 more outcomes

Named customers10 records

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered core and minor.

• SartoriuscoreStrategic or Co-development Partner · 17 September 2024Sartorius, a leading international partner of life sciences research and biopharmaceutical industry (€3.4 billion revenue in 2023, ~14,000 employees), brought LabTwin business into labforward GmbH and became a shareholder in the merged company. Supports labforward's growth in the digital transformation market.
• TECANminorStrategic or Co-development Partner · 17 September 2024Swiss company that is a financially and strategically involved partner in labforward GmbH alongside PVP and other investors.
• CARPUSminorStrategic or Co-development Partner · 1 January 2024Aachen-based laboratory planning specialist that has been strategically involved in labforward GmbH since early 2024.
• Helmholtz AssociationcoreStrategic or Co-development Partner · 1 January 2011Partnership started in 2011 with Germany's largest research organization (18 centers, 43,000+ employees, €5+ billion annual budget). PVP Advisors carries out external management of the Helmholtz Validation Fund, which has funded 50 internal projects bridging research results and marketable applications.
• CharitécoreStrategic or Co-development Partner · 1 January 2010Since 2010, PVP has been collaborating with Charité, one of Europe's leading university clinics. This partnership supports the Peppermint CBF 1 fund to promote translation of medical research into start-up ideas and provides access to a unique clinical research network for portfolio companies.
• PVP AdvisorscoreOthersSister company/spin-off of Peppermint Venture Partners that provides strategic advice and support for research organizations, foundations, and companies. Very closely connected with the start-up and innovation ecosystem.

Scale indicators6 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Forbion: Forbion is a leading European life sciences venture capital firm with offices in the Netherlands and Germany, focused on investing in early-to-late-stage biotech and MedTech companies. It is directly comparable to PVP given its sector-specialist mandate on European healthcare companies and similar stage focus.
• LSP (Life Sciences Partners): LSP is a long-standing Amsterdam-based European healthcare specialist VC firm investing across biotech, MedTech, and diagnostics. It is directly comparable to PVP in sector, geography, and stage focus, with a similar vertical-specialist investment thesis.
• Wellington Partners: Wellington Partners is a Munich-based European technology and life sciences VC firm investing across digital health, MedTech, and biotech. It is directly comparable to PVP given its DACH headquarters, sector focus overlap, and similar early-stage investment approach.
• Gilde Healthcare: Gilde Healthcare is a Utrecht-based European specialist investor in MedTech, therapeutics, and digital health. It is directly comparable to PVP given its DACH/Nordic focus, healthcare vertical specialization, and early-stage investment approach.
• HealthCap: HealthCap is a Nordic/European specialist life sciences VC firm based in Stockholm, investing in therapeutics and MedTech. It is directly comparable to PVP due to similar sector focus on European healthcare, comparable fund sizes, and similar stage focus.
• Advent Life Sciences: Advent Life Sciences is a London-based European life sciences venture capital firm investing in therapeutics and MedTech. It is directly comparable to PVP given its European healthcare focus, similar early-to-growth stage mandate, and similar fund sizes.
• Kurma Partners: Kurma Partners is a Paris-based European life sciences VC firm focused on therapeutics and MedTech. It is directly comparable to PVP given its pan-European healthcare specialization, similar sector focus, and early-to-mid-stage investment approach.
• TVM Capital Healthcare: TVM Capital Healthcare is a Munich-based, globally active healthcare specialist VC firm with European and Middle East operations. It is directly comparable to PVP given its German headquarters, life sciences vertical specialization, and similar investment stages.
• BioGeneration Ventures: BioGeneration Ventures is a Dutch-based European venture capital firm focused exclusively on early-stage life sciences companies. It is directly comparable to PVP given its similar early-stage focus, vertical specialization on European biotech/MedTech, and seed-to-Series A strategy.
• Andera Partners (Life Sciences): Andera Partners is a Paris-based European private equity firm with a dedicated Life Sciences vertical investing in biotech and MedTech. It is directly comparable to PVP given its European healthcare specialization and similar early-to-growth stage approach.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/peppermint_vp
• LinkedInde.linkedin.com/company/peppermint-venture-partners

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments16 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Peppermint Venture Partners